The Fifth Circuit GLP-1 shortage ruling came on August 27, 2026. In two unpublished per curiam opinions, the U.S. Court of Appeals for the Fifth Circuit upheld FDA’s decisions to remove tirzepatide injection products (No. 25-10600) and semaglutide injection products (No. 25-10758) from its drug shortage list. Both cases were brought by the Outsourcing Facilities Association and a compounding pharmacy against FDA.
Quick answer: What did the court decide? That FDA lawfully took tirzepatide and semaglutide injections off its shortage list. Compounders lost both appeals. The opinions are not designated for publication, and they do not decide whether shortage decisions require notice-and-comment rulemaking.
This article summarizes court records. It is not legal advice.
What were the two cases?
The plaintiffs in both were the Outsourcing Facilities Association and North American Custom Laboratories, doing business as FarmaKeio. Each appeal came from the U.S. District Court for the Northern District of Texas. The court decided them separately on the same day (Fifth Circuit, 2026a; 2026b).
The two Fifth Circuit appeals decided August 27, 2026
| Appeal | Drugs at issue | Intervenor | District court case | Result |
|---|---|---|---|---|
| No. 25-10600 | Tirzepatide (Mounjaro, Zepbound) | Eli Lilly and Company | 4:24-CV-953 | Affirmed |
| No. 25-10758 (revised September 1, 2026) | Semaglutide (Ozempic, Wegovy) | Novo Nordisk, Inc. | 4:25-CV-174 | Affirmed |
The shortage list matters for compounding. As the court put it, the law’s compounding prohibition on copies of approved drugs “is temporarily suspended when the drug product appears on the FDA’s drug shortage list.” FDA first posted that the tirzepatide shortage was resolved on October 2, 2024, reevaluated after the lawsuit, and confirmed it on December 19, 2024. For semaglutide, FDA’s declaratory order is dated February 21, 2025.
What did the court hold?
Notice and comment. The compounders argued FDA should have used notice-and-comment rulemaking. The court did not decide that question. “Assuming, without deciding,” that FDA erred, it found the compounders “have not met their burden to show prejudice.” In the tirzepatide case it noted they had actual notice, that FDA posted updates on its website, and that almost sixty days passed between FDA’s October 22, 2024 notice of reevaluation and its December 19 decision.
Arbitrary and capricious review. The court upheld FDA’s reliance on the manufacturers’ supply and demand data. In the tirzepatide case it found FDA disclosed the period it analyzed, reasonably used cumulative data, and reasonably found wholesaler screenshots, patient surveys, news reports and comments less probative. It agreed FDA could treat demand for compounded tirzepatide differently from demand for the approved drug. The court concluded that “the FDA engaged in reasoned decision-making.” The semaglutide opinion affirmed “for the same reasons.”
What does it change, and what does it not change?
It ends these appeals with FDA’s delisting decisions intact. FDA’s compounding page, last updated April 1, 2026, states that “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list” (FDA, 2026a).
It does not change the following:
- Precedent. Both opinions are marked “not designated for publication” under Fifth Circuit Rule 47.5.
- The procedure question. The court assumed, without deciding, that notice and comment might have been required.
- Other compounding rules. The rulings address the shortage list only. Our guides to compounded semaglutide and compounded tirzepatide cover what compounders may do now.
- Research material. The cases concern compounded medicines, not research reagents. Research-grade semaglutide and tirzepatide in our catalog are sold for laboratory research use only, not for human or veterinary use, and are not substitutes for approved or compounded medicines.
Who does it affect?
Outsourcing facilities and 503A pharmacies that compounded copies of these drugs during the shortages. Prescribers and patients who used compounded versions. Manufacturers: Eli Lilly and Novo Nordisk, whose data FDA relied on. Sellers and researchers: not addressed.
What happens next?
A separate track is still open. On May 1, 2026, FDA proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, which governs what outsourcing facilities may compound from bulk ingredients (FDA, 2026b). FDA extended the comment period to July 30, 2026 (FDA, 2026c). We found no final decision in the Federal Register through November 17, 2026.
How does it fit the earlier history?
The district court denied the compounders’ preliminary injunction motions on March 5, 2025 (tirzepatide) and April 24, 2025 (semaglutide), according to FDA’s page, and later granted summary judgment to FDA. The Fifth Circuit’s August rulings close the appeals from those judgments. For the full timeline, see compounded tirzepatide and the FDA, is tirzepatide legal and is semaglutide legal.
Frequently asked questions about the Fifth Circuit GLP-1 rulings
Who won the Fifth Circuit GLP-1 shortage appeals?
FDA, with Eli Lilly and Novo Nordisk as intervenors. The court affirmed both district court judgments.
Did the court say FDA must use notice and comment for shortage decisions?
No. It assumed, without deciding, that FDA may have erred, and held any error harmless.
Are tirzepatide and semaglutide on FDA’s shortage list now?
No. FDA’s page states they do not appear on the drug shortage list or the 503B bulks list.
What to know now
- Rulings: Fifth Circuit Nos. 25-10600 and 25-10758, August 27, 2026, both affirmed for FDA.
- Holdings: any notice-and-comment error was harmless; FDA’s shortage decisions were reasoned.
- Status: unpublished opinions; the procedure question was left open.
- Still pending: FDA’s final decision on the 503B bulks list proposal.
What we’re watching
Any request for rehearing or Supreme Court review in these cases. FDA’s final notice on semaglutide, tirzepatide and liraglutide for the 503B bulks list.